Search
supplier_code_of_conduct_010616_KR.pdf
supplier_code_of_conduct_010616_VN.pdf
supplier_code_of_conduct_010616_TH.pdf
Boehringer_Ingelheim_company_profile_2015.pdf
supplier_code_of_conduct_010616_TR.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
Lady, a guide dog in the office
A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.
Emmanuelle leads a team of scientists
Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
Informed decision and safe use of medications
Ingelvac CircoFLEX
For the active immunisation of pigs over the age of two weeks against porcine circovirus type 2 to reduce mortality, clinical signs – including weight loss – and lesions in lymphoid tissues associated with porcine circovirus diseases (PCVD).
Ingelvac MycoFLEX®
For the active immunisation of pigs from the age of three weeks to reduce lung lesions following infections with Mycoplasma hyopneumoniae.
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Corporate Profile
Corporate Profile
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.